Wyeth Pharmaceuticals started a process of re-engineering its drug discovery operations five years ago with the goal of improving its performance and identifying more clinical candidates. According to the firm, the process was a major success, and it has the numbers to back up that claim. Dr. Robert Ruffolo, president of research and development for Wyeth Pharmaceuticals, gave a talk last week at the PharmaDiscovery Conference in Washington, DC, describing the organizational changes and ways the firm maximized its use of drug discovery tools to improve productivity.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The ancestors of the Arizona bark scorpion and other scorpions and spiders underwent whole-genome duplication, KJZZ reports.

A cryptographic approach could help researchers keep genomic data private while researchers analyze it, Scientific American reports.

Andy Page, the former president of 23andMe, has joined a diabetes-management startup, according to CNBC.

In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.